Collaborative Home Visits to Reduce Hospital Readmissions and Improve Medication Use During Transitions of Care
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02087072|
Recruitment Status : Unknown
Verified October 2014 by Stuart Beatty, Ohio State University.
Recruitment status was: Active, not recruiting
First Posted : March 14, 2014
Last Update Posted : October 22, 2014
The primary objective is to develop a sustainable practice model emphasizing home visits by a collaborative physician and pharmacist team to decrease unplanned emergency department visits and hospital readmissions at 30 and 90 days for high-risk home bound patients. Secondary objectives include (1) tracking the number, type, and severity of adverse drug events (ADE) and potential adverse drug events (pADE) that occur following hospital discharge and (2) resolving any identified ADE and pADE within 7 days of hospital discharge.
Adult patients will be scheduled for a home visit by the Healthy at Home Columbus program at the time of hospital discharge. The home visit will occur within 7 days of hospital discharge and will consist of a complete hospital and medication review by a physician or nurse practitioner and a pharmacist (including all lab tests, imaging studies, medication changes, and proposed plan of care at the time of discharge). The investigators hypothesize these home visits will reduce 30 and 90 days hospital readmission rates and ED visits.
The number of emergency department visits and unplanned hospital readmissions will be tracked at 30 and 90 days following discharge from the hospitalization that led to study enrollment. A comparison cohort of patients discharged in the 12 months prior to study initiation will be used to compare the effectiveness of the home visit program. The number and type of adverse drug events (ADE) and potential adverse drug events (pADE) that occur during transitions of care will also be characterized. All ADE and pADE will be resolved during the initial home visit and will be classified based on severity. All ADE and pADE will be evaluated independently by two pharmacist reviewers; each reviewer will independently assign a severity rating to each ADE and pADE.
|Condition or disease||Intervention/treatment|
|Transitional Care Coordination Home Visits||Other: Collaborative visit with provider and pharmacist|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||COLLABORATIVE HOME VISITS TO REDUCE HOSPITAL READMISSIONS AND IMPROVE MEDICATION USE DURING TRANSITIONS OF CARE|
|Study Start Date :||October 2013|
|Estimated Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2014|
|Recently discharged homebound patients||
Other: Collaborative visit with provider and pharmacist
- Hospital Readmission [ Time Frame: 30 days ]
- Emergency Department Visit [ Time Frame: 30 days ]
- Number of drug related problems identified [ Time Frame: 30 days ]
- Type of drug related problems identified [ Time Frame: 30 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02087072
|United States, Ohio|
|The Ohio State University Division of General Internal Medicine Martha Morehouse|
|Columbus, Ohio, United States, 43221|